Pasithea Therapeutics Corp. (KTTA) stock forecast & analysis
0.5143
NasdaqCM · USDDelayed by 15 minutes
Down: -0.0157, -3.0%
1 analysis
Latest analysis: · verdict locked
- Open
- 0.5251
- Previous close
- 0.5300
- Day range
- 0.5101 – 0.5300
- 52-week range
- 0.2810 – 2.06
- Volume (shares)
- 502.59K
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 33.41M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- 0.44
- Market cap
- 17.19M
Market Scanner’s AI analysis of Pasithea Therapeutics Corp. (KTTA), updated November 2026: KTTA's FDA IND clearance for PAS-004 and positive clinical data presentation were key recent events.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Pasithea Therapeutics Corp. (KTTA) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
KTTA's FDA IND clearance for PAS-004 and positive clinical data presentation were key recent events.
Recent analyses covered KTTA's FDA IND clearance for PAS-004, targeting NF1-associated cutaneous neurofibromas, following positive clinical data presentations. The market analyst report detailed recent price action, technical indicators such as RSI and MFI suggesting strong buying pressure, and MACD indicating bearish momentum. The fundamentals analyst report outlined the company's financial performance, including operating and net losses in recent quarters and fiscal years, alongside its asset and liability figures.
KTTA news & sentiment
News reports highlighted FDA clearance for PAS-004 and positive clinical data, alongside investor events. Social media discussion centered on the NF1 indication and upcoming trial data.
KTTA technical picture
KTTA's price action showed a 7-day gain and a 30-day gain, trading above its 50-day SMA but below its 200-day SMA. Momentum indicators suggested strong buying pressure and upward momentum, though MACD readings indicated bearish momentum. The price was noted to be trading above the upper Bollinger Band.
Fundamentals
Pasithea Therapeutics Corp. reported operating and net losses in its most recent fiscal year and quarter. The company's fiscal year 2022 showed a gross profit from its cost of revenue. As of June 30, 2026, the company's total assets significantly exceeded its total liabilities, resulting in substantial shareholder equity.
Factors discussed — upside
- FDA clearance for Investigational New Drug (IND) application for PAS-004
- Positive clinical data from Phase 1 advanced cancer study presented at ESMO Congress 2026
- Initial data from ongoing Phase 1/1b trial in adult NF1 patients presented at 2026 European Neurofibromatosis Conference
- RSI at 63.95 indicating strong upward momentum
- MFI at 87.50 in overbought territory, suggesting strong buying pressure
Factors discussed — risks
- Operating income of -$5,713,282 USD in the most recent reported quarter
- Net income of -$5,273,852 USD in the most recent reported quarter
- Operating income of -$20,857,295 USD for fiscal year 2025
- Net income of -$20,427,683 USD for fiscal year 2025
- MACD at -0.0162, below zero, suggesting bearish momentum
- FDA clearance
- Clinical data presentation
- Technical indicators
- Financial performance
Summary updated .
KTTA technical indicators
Common technical indicators for KTTA, computed from its daily closing prices.
| Indicator | Value | Reading |
|---|---|---|
| 50-day simple moving average | 0.48 | Price above |
| 10-day exponential moving average | 0.44 | Price above |
| Relative strength index (14-day) | 61.05 | Neutral |
| MACD line (12/26/9) | -0.0075 | Above its signal line |
| Bollinger bands (20-day, 2σ) | 0.34 – 0.51 | Price inside the bands |
Analyses
Recent KTTA.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-04 KTTA.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Pasithea Therapeutics Corp.?
- Pasithea Therapeutics Corp. has received FDA clearance for its Investigational New Drug (IND) application for PAS-004, targeting NF1-associated cutaneous neurofibromas. This follows positive clinical data presentations from its Phase 1 advanced cancer study and an ongoing Phase 1/1b trial in adult NF1 patients. Technical indicators such as a strong RSI and an MFI in overbought territory suggest significant buying pressure.
- What are the risks for Pasithea Therapeutics Corp.?
- Pasithea Therapeutics Corp. reported operating and net losses in its most recent reported quarter and for the fiscal year 2025. The MACD indicator suggests bearish momentum, and the company's stock price remains below its 200-day simple moving average.
- Is Pasithea Therapeutics Corp. bullish or bearish?
- Recent AI analyses of Pasithea Therapeutics Corp. examined factors on both sides. Discussed upside: Pasithea Therapeutics Corp. has received FDA clearance for its Investigational New Drug (IND) application for PAS-004, targeting NF1-associated cutaneous neurofibromas. This follows positive clinical data presentations from its Phase 1 advanced cancer study and an ongoing Phase 1/1b trial in adult NF1 patients. Technical indicators such as a strong RSI and an MFI in overbought territory suggest significant buying pressure. Discussed risks: Pasithea Therapeutics Corp. reported operating and net losses in its most recent reported quarter and for the fiscal year 2025. The MACD indicator suggests bearish momentum, and the company's stock price remains below its 200-day simple moving average. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Pasithea Therapeutics Corp.?
- News reports highlighted FDA clearance for PAS-004 and positive clinical data, alongside investor events. Social media discussion centered on the NF1 indication and upcoming trial data.
- How does Market Scanner analyse Pasithea Therapeutics Corp.?
- Every analysis of Pasithea Therapeutics Corp. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Pasithea Therapeutics Corp.?
Pasithea Therapeutics Corp. has received FDA clearance for its Investigational New Drug (IND) application for PAS-004, targeting NF1-associated cutaneous neurofibromas. This follows positive clinical data presentations from its Phase 1 advanced cancer study and an ongoing Phase 1/1b trial in adult NF1 patients. Technical indicators such as a strong RSI and an MFI in overbought territory suggest significant buying pressure.
What are the risks for Pasithea Therapeutics Corp.?
Pasithea Therapeutics Corp. reported operating and net losses in its most recent reported quarter and for the fiscal year 2025. The MACD indicator suggests bearish momentum, and the company's stock price remains below its 200-day simple moving average.
Is Pasithea Therapeutics Corp. bullish or bearish?
Recent AI analyses of Pasithea Therapeutics Corp. examined factors on both sides. Discussed upside: Pasithea Therapeutics Corp. has received FDA clearance for its Investigational New Drug (IND) application for PAS-004, targeting NF1-associated cutaneous neurofibromas. This follows positive clinical data presentations from its Phase 1 advanced cancer study and an ongoing Phase 1/1b trial in adult NF1 patients. Technical indicators such as a strong RSI and an MFI in overbought territory suggest significant buying pressure. Discussed risks: Pasithea Therapeutics Corp. reported operating and net losses in its most recent reported quarter and for the fiscal year 2025. The MACD indicator suggests bearish momentum, and the company's stock price remains below its 200-day simple moving average. These are descriptive observations, not a recommendation.
What is the latest sentiment on Pasithea Therapeutics Corp.?
News reports highlighted FDA clearance for PAS-004 and positive clinical data, alongside investor events. Social media discussion centered on the NF1 indication and upcoming trial data.
How does Market Scanner analyse Pasithea Therapeutics Corp.?
Every analysis of Pasithea Therapeutics Corp. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh KTTA.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.